Memphasys (ASX:MEM) has signed a five-year commercial supply agreement with Centro Fertilita Assistita Italia, one of Italy's largest private IVF groups based in Naples.
The agreement, valued at a minimum of €525,000, includes the purchase of 3,000 Felix cartridges in the first two years and 1,500 cartridges annually thereafter, totaling 7,500 cartridges over the contract term.
Ahead of CE Mark approval, CFA Italia has placed an initial order for 500 Felix cartridges with revenue recognised this quarter and cash expected next quarter.
This early order reflects strong clinical demand generated through Memphasys' direct commercialisation model, following on-site training and clinical onboarding.
The deal marks Memphasys' first commercial contract in mainland Europe, expanding its footprint alongside agreements in Japan, India, and the Middle East.
CFA Italia's established relationships with IVF clinics across Italy offer a substantial opportunity to promote and distribute Felix, supporting rapid market adoption and potential to exceed minimum contracted volumes.
Marjan Mikel, Memphasys Non-Executive Director and Chair of Commercialisation, said the agreement "provides an immediate entry point into the Italian IVF market with a committed supply pathway and clear scalability" and positions the company to accelerate adoption ahead of CE Marking expected in early 2026.